Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2-metastatic breast cancer.

被引：15
|
作者：
Mayer, Erica L.
Wander, Seth Andrew
Regan, Meredith M.
DeMichele, Angela
Forero-Torres, Andres
Rimawi, Mothaffar F.
Ma, Cynthia X.
Cristofanilli, Massimo
Anders, Carey K.
Bartlett, Cynthia Huang
Winer, Eric P.
Burstein, Harold J.
机构：
[1] Dana Farber Canc Inst, Waban, MA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[4] Univ Alabama Birmingham, Birmingham, AL USA
[5] Baylor Coll Med, Houston, TX 77030 USA
[6] Washington Univ, Sch Med St Louis, St Louis, MO USA
[7] Northwestern Univ, Robert H Lurie Canc Ctr, Feinberg Sch Med, Chicago, IL USA
[8] Univ N Carolina, Chapel Hill, NC 27515 USA
[9] Pfizer Inc, Collegeville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS1104
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1104
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2-metastatic breast cancer patients compared to endocrine therapy alone - A large institutional study
    Raghavendra, Akshara Singareeka
    Ha, Min Jin
    Kettner, Nicole M.
    Damodaran, Senthil
    Layman, Rachel
    Hunt, Kelly K.
    Shen, Yu
    Tripathy, Debu
    Keyomarsi, Khandan
    CANCER RESEARCH, 2022, 82 (04)
  • [22] Time-to-failure in 1st-line endocrine therapy with ER+/HER2-metastatic breast cancer
    Nishimura, S.
    Akiyoshi, S.
    Koga, C.
    Oikawa, M.
    Nskamura, Y.
    Ishida, M.
    Ohno, S.
    BREAST, 2015, 24 : S82 - S83
  • [23] Phase Ib expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER plus metastatic breast cancer
    Layman, Rachel
    Wesolowski, Robert
    Han, Hyo
    Specht, Jennifer M.
    Stringer-Reasor, Erica M.
    Dees, E. Claire
    Kabos, Peter
    Mayer, Ingrid A.
    Vaishampayan, Ulka
    Lu, Janice
    Gogineni, Keerthi
    Bardia, Aditya
    Schott, Anne F.
    Abu-Khalaf, Maysa
    Howkins, Doug
    Sullivan, Brian
    Gorbatchevsky, Igor
    Rugo, Hope
    CANCER RESEARCH, 2022, 82 (04)
  • [24] A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with ER/HER2-metastatic breast cancer (MBC)
    Llombart-Cussac, Antonio
    Bellet, Meritxell
    Zamora, Pilar
    Ruiz, Manuel
    Gligorov, Joseph
    Di Cosimo, Serena
    Schmid, Peter
    Dawood, Shaheenah
    Roche, Henri
    Marme, Frederic
    Aguirre, Elena
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] CAPItello-292: A phase Ib/III study of capivasertib, palbociclib and fulvestrant, versus placebo, palbociclib and fulvestrant, for endocrine therapy-resistant HR+/HER2-advanced breast cancer
    Rugo, Hope S.
    Schiavon, Gaia
    Grinsted, Lynda M.
    De Bruin, Elza C.
    Catanese, Maria Teresa
    Hamilton, Erika
    CANCER RESEARCH, 2022, 82 (04)
  • [26] A Phase II Trial of Onapristone and Fulvestrant for Patients With ER + and HER2-Metastatic Breast Cancer
    Kamaraju, Sailaja
    Fowler, Amy M.
    Tarima, Sergey
    Chaudhary, Lubna N.
    Burkard, Mark E.
    Giever, Thomas
    Cheng, Yee C.
    Parkes, Amanda
    Lange, Carol A.
    Pipp-Dahm, Michele
    Hegeman, Robert
    Siddiqui, Nauman
    Stella, Amy
    Rajguru, Saurabh
    Twaroski, Kyleigh
    Zurbriggen, Luke
    Jorns, Julie M.
    Rui, Hallgeir
    Keigley, Quinton J.
    Perlman, Scott B.
    Salem, Kelley
    Bradshaw, Tyler J.
    Sahmoud, Tarek
    Wisinski, Kari
    CLINICAL BREAST CANCER, 2025, 25 (03) : 251 - 260
  • [27] A randomised phase II trial of palbociclib and fulvestrant vs standard endocrine therapy in patients with ER positive HER2 negative breast cancer and ctDNA detected molecular relapse during adjuvant endocrine therapy (TRAK-ER)
    Turner, Nicholas
    Phillips, Edward R.
    Bunce, Catey
    Robert, Marie
    Bailleux, Caroline
    Garcia-Murillas, Isaac
    Khabra, Komel
    Macpherson, Iain
    O'Brien, Ciara S.
    Okines, Alicia F.
    Palmieri, Carlo
    Schmid, Peter
    Swift, Claire
    Yara, Sabrina
    Connolly, Simon
    Lemonnier, Jerome
    Lee, Dymphna
    Andre, Fabrice
    CANCER RESEARCH, 2023, 83 (05)
  • [28] Real-World Comparison of Overall Survival in Female Patients with HR+/HER2-Metastatic breast cancer receiving endocrine therapy, endocrine therapy plus palbociclib, or chemotherapy
    Rizwan, U.
    Hussain, R.
    Kanagala, G.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 54 - 55
  • [29] HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2-metastatic breast cancer
    Shah, Payal Deepak
    Torres, Alexandra
    Aaron, Megan
    Narayan, Vivek
    Knollman, Hayley Michelle
    Bradbury, Angela R.
    DeMichele, Angela
    Robson, Mark E.
    Tung, Nadine M.
    Domchek, Susan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Open-label phase II study of everolimus plus endocrine therapy in post-menopausal women with ER+, HER2-metastatic breast cancer (Chloe trial)
    Shien, T.
    Shimomura, A.
    Uemura, Y.
    Kato, H.
    Kitada, M.
    Kikawa, Y.
    Shiba, E.
    Yoshida, T.
    Morimoto, T.
    Toyama, T.
    Aihara, T.
    Mukai, H.
    ANNALS OF ONCOLOGY, 2017, 28
12345